Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Multiple Sclerosis

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 115 articles:
HTML format



Single Articles


    March 2024
  1. HAHAM N, Zveik O, Rechtman A, Brill L, et al
    Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
    J Neuroimmunol. 2024;388:578289.
    PubMed     Abstract available


  2. CHANG EH, Hardy TA
    Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
    J Neuroimmunol. 2024;389:578330.
    PubMed     Abstract available


  3. FOGEL A, Olcer M, Goel A, Feng X, et al
    Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2024;389:578328.
    PubMed     Abstract available


    February 2024
  4. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
    Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
    J Neuroimmunol. 2024;387:578286.
    PubMed     Abstract available


  5. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
    EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
    J Neuroimmunol. 2024;389:578314.
    PubMed     Abstract available


  6. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
    Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
    J Neuroimmunol. 2024;389:578313.
    PubMed     Abstract available


  7. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
    Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2024;388:578299.
    PubMed     Abstract available


    January 2024
  8. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
    Dysregulated autotaxin expression by T cells in multiple sclerosis.
    J Neuroimmunol. 2024;387:578282.
    PubMed     Abstract available


  9. FUJIMORI J, Nakashima I
    Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    J Neuroimmunol. 2024;387:578280.
    PubMed     Abstract available


    December 2023
  10. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
    Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    J Neuroimmunol. 2023;387:578268.
    PubMed     Abstract available


  11. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
    Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
    J Neuroimmunol. 2023;387:578270.
    PubMed     Abstract available


  12. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
    Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
    J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
    PubMed     Abstract available


    November 2023
  13. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
    Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
    J Neuroimmunol. 2023;385:578240.
    PubMed     Abstract available


    October 2023
  14. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
    Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2023;385:578226.
    PubMed     Abstract available


    September 2023
  15. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
    Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
    J Neuroimmunol. 2023;383:578202.
    PubMed     Abstract available


  16. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
    Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
    J Neuroimmunol. 2023;384:578200.
    PubMed     Abstract available


  17. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
    Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    J Neuroimmunol. 2023;383:578199.
    PubMed     Abstract available


  18. PERDAENS O, van Pesch V
    MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
    J Neuroimmunol. 2023;386:578196.
    PubMed     Abstract available


    August 2023
  19. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
    Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2023;383:578178.
    PubMed     Abstract available


  20. BALAZS I, Horvath A, Heschl B, Khalil M, et al
    Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases.
    J Neuroimmunol. 2023;381:578136.
    PubMed     Abstract available


  21. SOTTINI A, Quaresima V, Barbaro M, Moiola L, et al
    Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.
    J Neuroimmunol. 2023;382:578170.
    PubMed     Abstract available


  22. BRUNE-INGEBRETSEN S, Hogestol EA, de Rosbo NK, Berg-Hansen P, et al
    Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis.
    J Neuroimmunol. 2023;382:578175.
    PubMed     Abstract available


    July 2023
  23. ADAMEC I, Brecl Jakob G, Rajda C, Drulovic J, et al
    Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    J Neuroimmunol. 2023;382:578164.
    PubMed     Abstract available


  24. PRIEGO M, Noriega L, Kalinin S, Hoffman LM, et al
    Genetic deletion of c-Jun amino-terminal kinase 3 (JNK3) modestly increases disease severity in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2023;382:578152.
    PubMed     Abstract available


    June 2023
  25. ELKJAER ML, Lohse RM, Burton M, Mendoza JP, et al
    Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
    J Neuroimmunol. 2023;381:578145.
    PubMed     Abstract available


  26. BLASK C, Schulze J, Rumpel S, Susse M, et al
    Modulation of cytokine release from peripheral blood mononuclear cells from multiple sclerosis patients by coenzyme A and soraphen A.
    J Neuroimmunol. 2023;381:578135.
    PubMed     Abstract available


  27. SI W, Ni Y, Jiang Q, Tan L, et al
    Nanopore sequencing identifies differentially methylated genes in the central nervous system in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2023;381:578134.
    PubMed     Abstract available


  28. CARIA P, Pilotto S, D'Alterio MN, Fronza M, et al
    Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium.
    J Neuroimmunol. 2023;381:578137.
    PubMed     Abstract available


  29. MICHETTI L, Maffina F, Ravasio R, Barcella V, et al
    Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases.
    J Neuroimmunol. 2023;379:578091.
    PubMed     Abstract available


  30. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Cerebrospinal fluid soluble CD27 is associated with CD8(+) T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2023;381:578128.
    PubMed     Abstract available


    May 2023
  31. MARSTERS C, Nathoo N, Amatto L, Wong R, et al
    Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
    J Neuroimmunol. 2023;380:578110.
    PubMed     Abstract available


  32. GE A, Sun Y, Kiker T, Zhou Y, et al
    A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis.
    J Neuroimmunol. 2023;379:578105.
    PubMed     Abstract available


  33. MANZANO GS, Rice DR, Zurawski J, Jalkh Y, et al
    Familial Mediterranean Fever and multiple sclerosis treated with ocrelizumab: Case report.
    J Neuroimmunol. 2023;379:578099.
    PubMed     Abstract available


  34. XUE Y, Zhang L, Guo R, Shao X, et al
    miR-485 regulates Th17 generation and pathogenesis in experimental autoimmune encephalomyelitis through targeting STAT3.
    J Neuroimmunol. 2023;379:578100.
    PubMed     Abstract available


    April 2023
  35. MULLER-MINY L, Heming M, Lautwein T, Ruck T, et al
    Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2023;378:578088.
    PubMed     Abstract available


  36. VACARAS V, Muresanu DF, Buzoianu AD, Nistor C, et al
    The role of multiple sclerosis therapies on the dynamic of human gut microbiota.
    J Neuroimmunol. 2023;378:578087.
    PubMed     Abstract available


    March 2023
  37. ABBADESSA G, Miele G, Cavalla P, Valentino P, et al
    Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.
    J Neuroimmunol. 2023;378:578072.
    PubMed     Abstract available


  38. FERREIRA F, Ferreira D, Guimaraes J, Soares-Dos-Reis R, et al
    Recurrent encephalopathy associated with pegylated beta-interferon treatment.
    J Neuroimmunol. 2023;376:578037.
    PubMed     Abstract available


  39. PALACIO PL, Pleet ML, Reategui E, Magana SM, et al
    Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.
    J Neuroimmunol. 2023;377:578064.
    PubMed     Abstract available


    January 2023
  40. SERAFINI B, Rosicarelli B, Veroni C, Aloisi F, et al
    Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein-Barr virus infected B cells.
    J Neuroimmunol. 2023;376:578036.
    PubMed     Abstract available


    December 2022
  41. CURRAN C, Vaitaitis G, Waid D, Volmer T, et al
    Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS).
    J Neuroimmunol. 2022;374:578008.
    PubMed     Abstract available


    November 2022
  42. SHU Y, Ma X, Chen C, Wang Y, et al
    Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.
    J Neuroimmunol. 2022;372:577937.
    PubMed     Abstract available


    October 2022
  43. LI X, Chu Y, Ma R, Dou M, et al
    Ferroptosis as a mechanism of oligodendrocyte loss and demyelination in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;373:577995.
    PubMed     Abstract available


  44. CUTELLE C, Balducci C, Cereda D, Fusco ML, et al
    K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis.
    J Neuroimmunol. 2022;373:577992.
    PubMed     Abstract available


  45. DE SOUZA TIEPPO EM, da Silva TFF, de Araujo RS, Silva GD, et al
    Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report.
    J Neuroimmunol. 2022;373:577991.
    PubMed     Abstract available


  46. FEIZI P, Sharma K, Pasham SR, Nirwan L, et al
    Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review.
    J Neuroimmunol. 2022;371:577939.
    PubMed     Abstract available


    September 2022
  47. FARAJI J, Gustafson C, Bettenson D, Negoro H, et al
    Bladder dysfunction in experimental autoimmune encephalomyelitis reflects clinical severity: A pilot study.
    J Neuroimmunol. 2022;372:577973.
    PubMed     Abstract available


  48. MAGALASHVILI D, Mandel M, Dreyer-Alster S, Didikin M, et al
    Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
    J Neuroimmunol. 2022;372:577966.
    PubMed     Abstract available


    July 2022
  49. ALOISI F, Cross AH
    MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
    J Neuroimmunol. 2022;371:577935.
    PubMed     Abstract available


  50. FUCHS L, Mausner-Fainberg K, Luban A, Asseyer SE, et al
    CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
    J Neuroimmunol. 2022;371:577936.
    PubMed     Abstract available


  51. DAS NEVES SP, Serre-Miranda C, Sousa JC, Costa PS, et al
    Lipocalin-2 does not influence EAE clinical score but it increases inflammation in central nervous system.
    J Neuroimmunol. 2022;368:577872.
    PubMed     Abstract available


  52. VAN DER WEELE L, Pollastro S, van Schaik BDC, van Kampen AHC, et al
    Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif) using B cell receptor repertoire analysis.
    J Neuroimmunol. 2022;370:577932.
    PubMed     Abstract available


  53. KASHEKE GDS, Holman SP, Robertson GS
    Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;370:577926.
    PubMed     Abstract available


    June 2022
  54. CHAN F, Riminton DS, Ramanathan S, Reddel SW, et al
    Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to "overlap" cases.
    J Neuroimmunol. 2022;369:577904.
    PubMed     Abstract available


    April 2022
  55. KYLLESBECH C, Trier N, Slibinskas R, Ciplys E, et al
    Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.
    J Neuroimmunol. 2022;367:577868.
    PubMed     Abstract available


    March 2022
  56. TOTTENHAM I, Koch M, Camara-Lemarroy C
    Serum HGF and APN2 are associated with disability worsening in SPMS.
    J Neuroimmunol. 2022;364:577803.
    PubMed     Abstract available


  57. SALARI AA, Jand Y, Ghazi-Khansari M
    Antibiotic treatment during pregnancy and lactation in dams exacerbates clinical symptoms and inflammatory responses in offspring with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;366:577840.
    PubMed     Abstract available


    January 2022
  58. KALININ S, Boullerne AI, Feinstein DL
    Serum levels of lipocalin-2 are elevated at early times in African American relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2022;364:577810.
    PubMed     Abstract available


  59. YE F, Dai Y, Wang T, Liang J, et al
    Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2022;364:577809.
    PubMed     Abstract available


  60. BRORSON IS, Eriksson AM, Hogestol E, Leikfoss IS, et al
    Global DNA methylation changes in treated and untreated MS patients measured over time.
    J Neuroimmunol. 2022;364:577808.
    PubMed     Abstract available


    December 2021
  61. TALBOT J, Hojsgaard Chow H, Holm Hansen R, von Essen MR, et al
    Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
    J Neuroimmunol. 2021;361:577756.
    PubMed     Abstract available


  62. KESHVARI MK, van Someren F, Sheikh S, Galea I, et al
    Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns.
    J Neuroimmunol. 2021;361:577729.
    PubMed     Abstract available


  63. ADAMEC I, Rogic D, Penz MG, Braun C, et al
    Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
    J Neuroimmunol. 2021;362:577788.
    PubMed     Abstract available


  64. TOLJAN K, Amin M, Kunchok A, Ontaneda D, et al
    New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.
    J Neuroimmunol. 2021;362:577785.
    PubMed     Abstract available


    November 2021
  65. CARAVAGNA C
    Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.
    J Neuroimmunol. 2021;362:577780.
    PubMed    


  66. HASSANSHAHI G, Noroozi Karimabad M, Jebali A
    The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
    J Neuroimmunol. 2021;362:577768.
    PubMed     Abstract available


  67. FREEDMAN MS, Wojcik J, Holmberg KH, Fluck M, et al
    Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
    J Neuroimmunol. 2021;360:577715.
    PubMed     Abstract available


  68. PACHE F, Ringelstein M, Aktas O, Kleiter I, et al
    C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    J Neuroimmunol. 2021;360:577699.
    PubMed     Abstract available


  69. MASCIA E, Clarelli F, Zauli A, Guaschino C, et al
    Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.
    J Neuroimmunol. 2021;362:577760.
    PubMed     Abstract available


    October 2021
  70. VAKRAKOU AG, Tzanetakos D, Evangelopoulos ME, Fragoulis GE, et al
    IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;361:577759.
    PubMed     Abstract available


  71. FUJIMORI J, Miyazawa K, Nakashima I
    Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neuroimmunol. 2021;361:577755.
    PubMed     Abstract available


  72. ACHIRON A, Mandel M, Dreyer-Alster S, Harari G, et al
    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
    J Neuroimmunol. 2021;361:577746.
    PubMed     Abstract available


    September 2021
  73. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    PubMed     Abstract available


    August 2021
  74. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    PubMed     Abstract available


  75. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    PubMed     Abstract available


  76. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed     Abstract available


  77. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed     Abstract available


  78. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    PubMed     Abstract available


    July 2021
  79. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    PubMed     Abstract available


  80. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    PubMed     Abstract available


  81. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    PubMed     Abstract available


  82. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available


  83. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available


    June 2021
  84. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    PubMed     Abstract available


  85. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available


  86. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available


  87. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available


    May 2021
  88. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available


  89. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available


  90. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available


    April 2021
  91. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.
    PubMed    


  92. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available


  93. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available


  94. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available


    March 2021
  95. LAZAREVIC M, Djedovic N, Stanisavljevic S, Dimitrijevic M, et al
    Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies.
    J Neuroimmunol. 2021;354:577547.
    PubMed     Abstract available


  96. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
    Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    J Neuroimmunol. 2021;354:577541.
    PubMed     Abstract available


    February 2021
  97. XIANG W, Xie C, Guan Y
    The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis.
    J Neuroimmunol. 2021;354:577520.
    PubMed     Abstract available


  98. LUCCHINI M, Giuffre GM, Nociti V, Bianco A, et al
    Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis.
    J Neuroimmunol. 2021;353:577525.
    PubMed     Abstract available


  99. UCHIDA N, Mori K, Fujita-Nakata M, Nakanishi M, et al
    Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
    J Neuroimmunol. 2021;353:577500.
    PubMed     Abstract available


  100. LI Q, Liu Y, Zeng Y
    Questions about data: Importance of serum amyloid A level in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577516.
    PubMed    


    January 2021
  101. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
    An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577507.
    PubMed     Abstract available


  102. MIMPEN M, Rolf L, Muris AH, Gerlach O, et al
    NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.
    J Neuroimmunol. 2021;353:577499.
    PubMed     Abstract available


  103. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
    Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577497.
    PubMed     Abstract available


  104. NIU Y, Li Y
    The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.
    J Neuroimmunol. 2021;352:577465.
    PubMed    


  105. ZILIOTTO N, Lamberti N, Manfredini F, Straudi S, et al
    Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
    J Neuroimmunol. 2021;352:577473.
    PubMed     Abstract available


    December 2020
  106. STASCHEIT F, Li L, Mai K, Baum K, et al
    Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.
    J Neuroimmunol. 2020;351:577469.
    PubMed     Abstract available


  107. YOKOTE H, Toru S, Nishida Y, Hattori T, et al
    Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.
    J Neuroimmunol. 2020;351:577466.
    PubMed     Abstract available


  108. GARCIA-FERNANDEZ FJ, Garcia-Fernandez AE, Nava E, Del Pozo JSG, et al
    A bibliometric evaluation of the top 100 cited natalizumab articles.
    J Neuroimmunol. 2020;349:577379.
    PubMed     Abstract available


    November 2020
  109. BILGE N, Simsek F, Yevgi R, Ceylan M, et al
    Low serum Alpha-SYNUCLEIN and oligomer Alpha-SYNUCLEIN levels in multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577432.
    PubMed     Abstract available


  110. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577433.
    PubMed     Abstract available


  111. GONCALVES MVM, Brandao WN, Longo C, Peron JPS, et al
    Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
    J Neuroimmunol. 2020;350:577435.
    PubMed     Abstract available


    October 2020
  112. MARTINEZ-LARROSA J, Matute-Blanch C, Montalban X, Comabella M, et al
    Modelling multiple sclerosis using induced pluripotent stem cells.
    J Neuroimmunol. 2020;349:577425.
    PubMed     Abstract available


    September 2020
  113. NEKRASOVA I, Shirshev S
    Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
    J Neuroimmunol. 2020;349:577421.
    PubMed     Abstract available


  114. HAWKE S, Zinger A, Juillard PG, Holdaway K, et al
    Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    J Neuroimmunol. 2020;349:577392.
    PubMed     Abstract available


    June 2020
  115. NAJJAR E, Staun-Ram E, Volkowich A, Miller A, et al
    Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    J Neuroimmunol. 2020;343:577230.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.